Intellia Therapeutics, Inc. (NTLA): Total Liabilities
$170.73M
As of 2025-12-31
$129.46M
As of 2026-06-30
-15.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $170.73M | -46.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $319.06M | +27.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $250.81M | -11.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $284.53M | n/a | 2024-02-22, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $338.60M | +3.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $1.25B | -8.7% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗